Literature DB >> 18417563

Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Chih-Jen Wei1, Ling Xu, Wing-Pui Kong, Wei Shi, Kevin Canis, James Stevens, Zhi-Yong Yang, Anne Dell, Stuart M Haslam, Ian A Wilson, Gary J Nabel.   

Abstract

Although the human transmission of avian H5N1 virus remains low, the prevalence of this highly pathogenic infection in avian species underscores the need for a preventive vaccine that can be made without eggs. Here, we systematically analyze various forms of recombinant hemagglutinin (HA) protein for their potential efficacy as vaccines. Monomeric, trimeric, and oligomeric H5N1 HA proteins were expressed and purified from either insect or mammalian cells. The immunogenicity of different recombinant HA proteins was evaluated by measuring the neutralizing antibody response. Neutralizing antibodies to H5N1 HA were readily generated in mice immunized with the recombinant HA proteins, but they varied in potency depending on their multimeric nature and cell source. Among the HA proteins, a high-molecular-weight oligomer elicited the strongest antibody response, followed by the trimer; the monomer showed minimal efficacy. The coexpression of another viral surface protein, neuraminidase, did not affect the immunogenicity of the HA oligomer, as expected from the immunogenicity of trimers produced from insect cells. As anticipated, HA expressed in mammalian cells without NA retained the terminal sialic acid residues and failed to bind alpha2,3-linked sialic acid receptors. Taken together, these results suggest that recombinant HA proteins as individual or oligomeric trimers can elicit potent neutralizing antibody responses to avian H5N1 influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417563      PMCID: PMC2447076          DOI: 10.1128/JVI.00187-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Authors:  J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

2.  Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

Authors:  J J Treanor; R F Betts; G E Smith; E L Anderson; C S Hackett; B E Wilkinson; R B Belshe; D C Powers
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

3.  Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.

Authors:  D L Lakey; J J Treanor; R F Betts; G E Smith; J Thompson; E Sannella; G Reed; B E Wilkinson; P F Wright
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

4.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.

Authors:  I A Wilson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

5.  Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus.

Authors:  James Stevens; Adam L Corper; Christopher F Basler; Jeffery K Taubenberger; Peter Palese; Ian A Wilson
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

6.  Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Authors:  D C Powers; G E Smith; E L Anderson; D J Kennedy; C S Hackett; B E Wilkinson; F Volvovitz; R B Belshe; J J Treanor
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

Review 7.  Influenza virus neuraminidase: structure, antibodies, and inhibitors.

Authors:  P M Colman
Journal:  Protein Sci       Date:  1994-10       Impact factor: 6.725

8.  Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity.

Authors:  Zhi-Yong Yang; Chih-Jen Wei; Wing-Pui Kong; Lan Wu; Ling Xu; David F Smith; Gary J Nabel
Journal:  Science       Date:  2007-08-10       Impact factor: 47.728

9.  Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Authors:  Zhi-yong Yang; Bimal K Chakrabarti; Ling Xu; Brent Welcher; Wing-pui Kong; Kwanyee Leung; Amos Panet; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 10.  Are we ready for pandemic influenza?

Authors:  Richard J Webby; Robert G Webster
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

View more
  72 in total

1.  Dendritic cell activation by recombinant hemagglutinin proteins of H1N1 and H5N1 influenza A viruses.

Authors:  Wen-Chun Liu; Shih-Chang Lin; Yen-Ling Yu; Ching-Liang Chu; Suh-Chin Wu
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

2.  Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets.

Authors:  Weijia Wang; Bin Lu; Helen Zhou; Amorsolo L Suguitan; Xing Cheng; Kanta Subbarao; George Kemble; Hong Jin
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

3.  Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.

Authors:  Hsin-Yu Liao; Shih-Chi Wang; Yi-An Ko; Kuo-I Lin; Che Ma; Ting-Jen Rachel Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

4.  Immunosilencing a highly immunogenic protein trimerization domain.

Authors:  Kwinten Sliepen; Thijs van Montfort; Mark Melchers; Gözde Isik; Rogier W Sanders
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

5.  The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.

Authors:  Amorsolo L Suguitan; Michael P Marino; Purvi D Desai; Li-Mei Chen; Yumiko Matsuoka; Ruben O Donis; Hong Jin; David E Swayne; George Kemble; Kanta Subbarao
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

6.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

7.  Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Authors:  Srinivas S Rao; Wing-Pui Kong; Chih-Jen Wei; Neal Van Hoeven; J Patrick Gorres; Martha Nason; Hanne Andersen; Terrence M Tumpey; Gary J Nabel
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

9.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

10.  Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Authors:  Mookkan Prabakaran; Selvaraj Madhan; Nayana Prabhu; Jia Qiang; Jimmy Kwang
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.